Bioidentical hormones for menopausal therapy

Women's Health

Volumn 4, Issue 2, 2008, Pages 163-171

  Sites, Cynthia K ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Biest; Bioidentical; Compounded; DHEA; Estradiol; Estriol; Hormone; Menopause; Progesterone; Testosterone

Indexed keywords

ELESTRIN; ESTRADIOL; ESTRADIOL PLUS ESTRIOL; ESTRADIOL PLUS ESTRIOL PLUS ESTRONE; ESTRIOL; ESTROGEN; ESTRONE; MEDROXYPROGESTERONE ACETATE; METHYLTESTOSTERONE; PLACEBO; PRASTERONE; PROGESTERONE; TESTOSTERONE; TESTOSTERONE UNDECANOATE; UNCLASSIFIED DRUG;

BINDING AFFINITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LIPID BLOOD LEVEL; LOW DRUG DOSE; MENOPAUSAL SYNDROME; MONOTHERAPY; NONHUMAN; REVIEW; SALIVA ANALYSIS; SIDE EFFECT; SKIN IRRITATION; SKIN SENSITIVITY; TRIACYLGLYCEROL BLOOD LEVEL; VAGINA ATROPHY; VAGINAL DRYNESS;

ADMINISTRATION, CUTANEOUS; DRUG COMPOUNDING; ESTRADIOL; ESTRIOL; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; PHYTOTHERAPY; PLANT EXTRACTS; PROGESTERONE; TESTOSTERONE;

EID: 41949138310     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.4.2.163     Document Type: Review

References (50)

1. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG: A prospective population-based study of menopausal symptoms. Obstet. Gynecol. 96(3), 351-358 (2000).
2. Gold EB, Colvin A, Avis N et al.: Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am. J. Public Health 96 (7), 1226-1235 (2006).
3. Rossouw JE, Anderson GL, Prentice RL et al.: Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288(3), 321-333 (2002).
4. Hulley S, Grady D, Bush T et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary artery disease. JAMA 280(7), 605-613 (1998).
5. Cirigliano M: Bioidentical hormone therapy: a review of the evidence. J. Womens Health 16 (5), 600-631 (2007).
6. Understanding the controversy: hormone testing and bioidentical hormones. Proceedings of the Postgraduate Course; 17th Annual Meeting of the North American Menopause Society. Nashville, TN, USA, 11 October 2006.
7. Pegues DA: Improving and enforcing compounding pharmacy practices to protect patients. Clin. Infect. Dis. 43, 838-840 (2006).
8. Somers S: In: The Sexy Years: Discover the Hormone Connection - the Secret to Fabulous Sex, Great Health, and Vitality for Women and Men. Crown Publishers, NY, USA (2004).
9. Platt ME: The Miracle of Bio-Identical Hormones: A Revolutionary Approach to Wellness for Men, Women, and Children. Clancy Lane Publishing, Palm Desert, CA, USA (2006).
10. Speroff L, Fritz MA: In: Clinical Gynecologic Endocrinology and Infertility. Lippincott Williams and Wilkins, Philadelphia, PA, USA (1995).
11. Lemon HM: Oestriol and prevention of breast cancer. Lancet 1, 546 (1973).
12. Lemon HM: Clinical and experimental aspects of the anti-mammary carcinogenic activity of estriol. Front. Horm. Res. 5, 155 (1977).
13. Lemon HM: Estriol prevention of mammary carcinoma induced by 7, 12-dimethylbenzanthracene and procarbazine. Cancer Res. 35, 1341 (1975).
14. Lemon HM: Antimammary carcinogenic activity of 17-alpha-ethinyl estriol. Cancer 60, 2873 (1987).
15. Lemon HM: Pathophysiologic considerations in the treatment of menopausal patients with oestrogens: mammary carcinoma. Acta Endocrinol. Suppl. (Copenh.) 233, 17-27 (1980).
16. Taylor M: Unconventional estrogens: Estriol, Biest, and Triest. Clin. Obstet. Gynecol. 44(4), 864-879 (2001).
17. Boothby LA, Doering PL, Kipersztok S: Bioidentical hormone therapy: a review. Menopause 11(3), 356-467 (2004).
18. Drug Facts and Comparisons, 5th Edition, Facts and comparisons, St Louis, MO, USA (2001).
19. Dessole S, Rubattu G, Ambrosini G et al.: Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women. Menopause 11(1), 49-56 (2004).
20. Kuiper GG, Carlsson B, Grandien K et al.: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138(3), 863-870 (1997).
21. Hall JM, McDonnell DP: Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol. Interv. 5, 343-357 (2005).
22. North American Menopause Society: Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of the North American Menopause Society. Menopause 14(2), 168-182 (4007).
23. Cincinelli E: Bioidentical estradiol gel for hormone therapy in menopause. Expert. Rev. of Obstet. Gynecol. 2(4), 423-430 (2007).
24. Naunton M, Al Hadithy AFY, Brouwers JR, Archer DF: Estradiol gel: review of the pharmacology, pharmacokinetics, efficacy, and safety in menopausal women. Menopause 13(3), 517-527 (2006).
25. Bachman GA, Schaefers M, Uddin A, Utian WF: Lowest effective transdermal 17β-estradiol dose for relief of hot flushes in postmenopausal women. Obstet. Gynecol. 110(4), 771-779 (2007).
26. Simon JA, Bouchard C, Waldbaum A, Utian W, Zborowski J, Snabes M: Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausl women. Obstet. Gynecol. 109(3), 588-596 (2007).
27. Johnson SR, Ettinger B, Macer JL, Ensrud KE, Quan J, Grady D: Uterine and vaginal effects of unopposed ultra low-dose transderminal estradiol. Obstet. Gynecol. 105(4), 779-787 (2005).
28. The Writing Group for the PEPI Trial: Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 275(5), 370-375 (1996).
29. Montplaisir J, Lorrain J, Denesle R, Petit D: Sleep in menopause: differential effects of two forms of hormone replacement therapy. Menopause 8(1), 10-16 (2001).
30. Wren BG, Day RO, McLachlan AJ, Williams KM: Pharmacokinetics of estradiol, progesterone, testosterone and dehydroepiandrosterone after transbuccal administration to postmenopausal women. Climacteric 6(2), 104-111 (2003).
31. Vashisht A, Wadsworth F, Carey A, Carey B, Studd J: A study to look at hormonal absorption of progesterone cream used in conjunction with transdermal estrogen. Gynecol. Endocrinol. 21(2), 101-105 (2005).
32. Wren BG, McFarland K, Edwards L: Micronised transdermal progesterone and endometrial response. Lancet 354(9188), 1447-1448 (1999).
33. Eden JA, Hacker NE, Fortune M: Three cases of endometrial cancer associated with 'bioidentical' hormone replacement therapy. Med. J. Aust. 187(4), 244-245 (2007).
34. Lee JR: Use of Pro-Gest cream in postmenopausal women. Lancet 352, 905 (1998).
35. Lee J: Natural progesterone. In: The Multiple Roles of a Remarkable Hormone. BLL Publishing, CA, USA (1993).
36. Lee JR, Zava D, Hopkins V: In: What Your Doctor May Not Tell You About Breast Cancer! How Hormone Balance Can Help Save Your Life. Warner Books, New York, NY, USA (2002).
37. Bachmann G, Bancroft J, Braunstein G et al.: Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. BLL Publishing, CA, USA 77(4), 660-665 (2002).
38. Hickock LR, Toomey C, Speroff L: A comparison of esterifted estrogens with and without methyltestosterone: effects on endornetrial histology and serum lipoproteins in postmenopausal women. Obstet Gynecol. 82(6), 919-924 (1993).
39. Chiuve SE, Martin LA, Campos H, Sacks FM: Effect of the combination of methyltestosterone and esterified estrogens compared with esterifted estrogens alone on apolipoprotein CIII and other apolipoproteins in very low density, low density, and high density lipoproteins in surgically menopausal women. J. Clin. Endocrinol. Metab. 89(5), 2207-2213 (2004).
40. Leao LM, Duarte MP, Silva DM, Bahia PR, Coeli CM, de Farias ML: Influence of methyltestosterone postmenopausal therapy on plasma lipids, inflammatory factors, glucose metabolism and visceral fat: a randomized study. Eur. J. Endocrinol. 154(1), 131-139 (2006).
41. Simon J, Braunstein G, Nachtigail L et al.: Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J. Clin. Endocrinol. Metab. 90(9), 5226-5233 (2005).
42. Panjari M, Davis SR: DHEA therapy for women: effect on sexual function and wellbeing. Human Reproduction Update 13(3), 239-248 (2007).
43. Raven PW, Hinson JP: Dehydroepiandrosterone (DHEA) and the menopause: an update. Menopause Int. 13(2), 75-78 (2007).
44. Walker CR: Bioidentical hormone replacement therapy. A natural option for perimenopause and beyond. Adv. Nurse Pract. 9(5), 39-42 (2001).
45. Marder MZ, Joshi U, Mandel ID: Estrogen concentration in human parotid and submaxillary saliva. J. Dent. Res. 58(12), 2370 (1979).
46. Lewis JG, McGill H, Patton VM, Elder PA: Caution on the use of saliva measurements to monitor absorption of progesterone from transdernial creams in postmenopausal women. Maturitas 41(1), 1-6 (2002).
47. Chatterton RT Jr, Mateo ET, Hou N et al.: Characteristics of salivary profiles of oestradiol and progesterone in premenopausal wornen. J. Endocrinol. 186(1), 77-84 (2005).
48. ACOG Committee on Gynecologic Practice: ACOG committee opinion number 322. Compounded bioidentical hormones. Obstet. Gynecol. 106(5), 1139-1140 (2005).
49. Mircioiu C, Perju A, Grin E et al.: Pharmacokinetics of progesterone in postmenopausal women: 2. Pharmacokinetics following percutaneous administration. Eur. J. Drug Metab. Pharmacokinet. 23(3), 397-402 (1998).
50. Mircioiu C, Perju A, Neagu A, Griu E, Calin G, Miron DS: Pharmacokinetics of progestrone in postmenopausal women: 1. Pharmacokinetics following intravaginal administration. Eur. J. Drug Metab. Pharmacokinet. 23(3), 391-396 (1998).